Clinical trials: Hospitalization
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID-19
ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04583956
- Testing
- Remdesivir, Risankizumab
- Where
- 32 sites in United States
- Volunteers
- 214 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Coronavirus
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04364737
- Testing
- Convalescent Plasma, Saline solution
- Where
- 9 sites in United States
- Volunteers
- 941 people
- Sponsor
- NYU Langone Health
Type 2 Diabetes Mellitus, Hyperglycemia
MedStar Health Type 2 Diabetes Pathway to Control
A Diabetes Institute (MDI), in partnership with key stakeholders-including Primary Care Providers- in a northeastern US regional, mixed-payer healthcare system), seeks to implement an evidence-based, technology-enabled…
- Trial name
- T2DMBC (NCT02925312)
- Testing
- Diabetes Pathway
- Where
- United States
- Volunteers
- 419 people
- Sponsor
- Medstar Health Research Institute
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
COVID-19
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19.
- Trial name
- NCT04822701
- Testing
- BI 767551 intravenous, BI 767551 inhaled
- Where
- 5 sites in United States, Spain
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Coronary Heart Disease
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS).
- Trial name
- NCT01323153
- Testing
- dalcetrapib
- Where
- 33 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19.
- Trial name
- SCOPE (NCT04341675)
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Cincinnati
Automated Communication Tools, Complex Medical Patients
Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care
Communication between physicians caring for a patient in the hospital and that patient's primary care provider is less than optimal, and can lead to diminished health care quality and safety.
- Trial name
- NCT01397253
- Testing
- Automated communication tools
- Where
- United States
- Volunteers
- 835 people
- Sponsor
- University of Pittsburgh
Severe Acute Respiratory Illness
Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Respiratory viruses are a significant cause of hospitalization for respiratory tract infections. This study will evaluate the safety, effectiveness, and tolerability of nitazoxanide (NTZ) in treating severe acute respiratory…
- Trial name
- NTZ-SARI (NCT02057757)
- Testing
- Nitazoxanide
- Where
- 6 sites in Mexico
- Volunteers
- 260 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
The purpose of this research study is to find out if CCP is safe and to determine the safest and most effective level of anti-viral antibody when given to people admitted to the hospital with confirmed COVID-19 infection.
- Trial name
- UNC CCP RCT (NCT04524507)
- Testing
- High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
Drinking, Alcohol
The Development of a Personalized, Real-time Intervention
The investigators propose to enhance our existing coping motive-specific normative feedback intervention (PFIcope intervention) by capitalizing on EMA/EMI technology to pair real-time affective monitoring with tailored real-time…
- Trial name
- PFIcope+EMI (NCT03518619)
- Testing
- PFIcope+EMI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Butler Hospital
Chronic Heart Failure
Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure
The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety…
- Trial name
- PHARM-CHF (NCT01692119)
- Testing
- Regular, pharmacy based intervention
- Where
- Germany
- Volunteers
- 258 people
- Sponsor
- Federal Union of German Associations of Pharmacists
Opioid Use Disorder, Medication Adherence
MHealth Incentivized Adherence Plus Patient Navigation
Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which…
- Conditions
- Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
- Trial name
- MIAPP (NCT06027814)
- Testing
- Patient Navigation and mHealth (PN+mHealth)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health
Ischemic Heart Disease
Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease
RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint.
- Trial name
- RESILIENT (NCT03978130)
- Testing
- mHealth-CR
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- NYU Langone Health
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
To show the superiority in safety of Smoflipid over Intralipid® as measured by the number of study patients in each treatment group with conjugated bilirubin exceeding 2 mg/dL during the first 28 days of study treatment…
- Trial name
- NCT02579265
- Testing
- Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
- Where
- 13 sites in United States
- Volunteers
- 204 people
- Sponsor
- Fresenius Kabi
Nicotine Dependence, Cigarettes
Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit
This study aims to pilot a method of collecting the post-discharge follow-up data required by the Joint Commission Tobacco Measure Set, using text messages sent to and received from patients' cellular-telephones.
- Trial name
- NCT02986711
- Testing
- Motivational Text Messages, Control
- Where
- United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Complicated Intra-abdominal Infection
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
Study C3591036 is a Phase 3 study to assess the efficacy and safety of PF-06947386 in Japanese adult patients with complicated intra-abdominal infection requiring hospitalization.
- Trial name
- NCT04927312
- Testing
- PF-06947386, Metronidazole
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim